Skip to main content
Log in

Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register

  • Original Article
  • Published:
International Archives of Occupational and Environmental Health Aims and scope Submit manuscript

Abstract

Between 1987 and 2000, the German mesothelioma register recorded a total of 4,455 patients with malignant mesotheliomas. Survival times for 498 (11.2%) patients were available; 155 patients (study group, 3.5% of the total group) survived for more than 2 years and 343 patients (control group, 7.7% of the total group) survived for fewer than 24 months. Male patients were over-represented in both groups, with 13% of women in the study and 4.4% in the control group. The proportion of pleural mesotheliomas was more than 90% in both groups, with peritoneal cases comprising 6.5% in the study group and 3.2% in the control group. Histologically, the epithelioid subtype was represented in 58% of the study group, whereas the biphasic subtype predominated (67.6%) in the control group. Only 7% of tumours were of the sarcomatoid subtype. The average age of patients in the study group was 57.4 years, thus lower than in the control group (62.8 years). Lung dust analysis showed an increased pulmonary asbestos burden in 94% of all patients; significant differences between the study and control group were not observed. In the majority of the total group pleural effusions were the first symptoms. Therapeutic data were available in fewer than 40% of all cases. Surgical interventions were performed, partly in combination with radiation and chemotherapy and as alternative treatments. Significant deviations in survival time dependent on therapy applied could not be proved. By multivariate analysis (Cox proportional hazards regression model) favourable prognostic factors for long-term survival were epithelioid tumour subtype, comparatively young age (<60 years), and female gender (P<0.05).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3a–c
Fig. 4
Fig 5
Fig. 6

Similar content being viewed by others

References

  1. Adams VI, Unni KK, Muhm JR, Jett JR, Ilstrup DM, Bernazt PE (1986) Diffuse malignant mesothelioma of the pleura. Diagnosis and survival in 92 cases. Cancer 58:1540–1551

    CAS  PubMed  Google Scholar 

  2. Agudo A Gonzales C, Bleda M, Ramirez J, Hernandez S, Lopez F, Calleja A, Panades R, Turuguet D, Escolar A, Beltran M, Gonzales-Moya JE (2000) Occupation and risk of malignant pleural mesothelioma. A case control study in Spain. Am J Ind Med 37:159–168

    Article  CAS  PubMed  Google Scholar 

  3. Antmann KH (1993) Natural history and epidemiology of malignant mesothelioma. Chest 103[Supp]:373S–76S

  4. Antmann KH, Shemin R, Ryan L (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients. The Dana Farber Institute and Brigham and Woman’s Hospital experience over two decades J Clin Oncol 6:147–153

    Google Scholar 

  5. Attanoos R, Gibbs AR (1998) Peritoneal mesothelioma: clinicopathological analysis of 227 cases from the UK mesothelioma register. Clin Exp Pathol 46:376–376

    Google Scholar 

  6. Baas P (2002) Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol 29:62–69

    Article  CAS  Google Scholar 

  7. Beer TW, Buchanan R, Mathews AW, Stradling R, Pullinger N, Pethybridge RJ (1998) Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype. Hum Pathol 29:246–251

    CAS  PubMed  Google Scholar 

  8. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1999) Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 40:1241–1245

    Google Scholar 

  9. Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C (1997) Latency periods in asbestos related mesothelioma of the pleura. Eur J Cancer Prev 6:162–166

    CAS  Google Scholar 

  10. Bischoff HG, Manegold C, Drings P (2000) Langzeit-Spontanverlauf beim malignen Pleuramesotheliom. Pneumologie 54:S31

    Google Scholar 

  11. Blecklake MR (1976) Asbestos related diseases of the lung and other organs: their epidemiology and implications for clinical practice. Am J Respir Dis 114:187–227

    Google Scholar 

  12. Brenner J, Sordillo PP, Magill MG, Golbey RB (1981) Malignant peritoneal mesothelioma: review of 25 patients. Am J Gastroenterol 75:311–313

    CAS  PubMed  Google Scholar 

  13. Brenner J, Sordillo PP, Magil GB, Golgey RB (1982) Malignant mesothelioma of the pleura. Cancer 49:2431–2435

    CAS  PubMed  Google Scholar 

  14. Brockmann M, Fischer M, Müller KM (1989) Lungenstaubanalyse bei Bronchialkarzinomen. Atemw Lungenkrkh 15:263–265

    Google Scholar 

  15. Browne K, Smither WJ (1983) Asbestos related mesothelioma: factors discriminating between pleural and peritoneal sites. Br J Ind Med 40:145–152

    CAS  PubMed  Google Scholar 

  16. Chahinian APH, Pajak TF, Holland JF, Norton L, Armbinder RM, Mandel EM (1982) Diffuse malignant mesothelioma (prospective evaluation of 69 patients) Ann Intern Med 96:746–755

    Google Scholar 

  17. Chailleux E, Dabouis G, Pioche D, deLajarte M, deLajarte AY, Rembeaux A, Germaud P (1988) Prognostic factors in diffuse malignant pleural mesothelioma. Chest 93:159–162

    CAS  PubMed  Google Scholar 

  18. Craighead JE (1982) Asbestos related diseases. Arch Pathol Lab Med 106:544–596

    CAS  PubMed  Google Scholar 

  19. Dienemman H, Trainer C (2000) Mesotheliom der Pleura und des Peritoneums. Chirurg 71:887–893

    Article  PubMed  Google Scholar 

  20. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O’Byrne KJ (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognosis scoring systems. Thorax 55:731–735

    Article  CAS  PubMed  Google Scholar 

  21. Ehlers EM, Kühnel W, Wiedemann GJ (2002) Hyperthermia and mafosfamide in a human derived malignant pleural mesothelioma cell line. J Cancer Res Clin Oncol 128:65–72

    Article  CAS  PubMed  Google Scholar 

  22. Elmes PC, Simpson JC (1976) The clinical aspects of mesothelioma. Q J Med 45:427–449

    PubMed  Google Scholar 

  23. Fizazi K, John WJ, Vogelzang NJ (2002) The emerging role of antifolates in the treatment of malignant mesothelioma. Semin Oncol 1:77–81

    Article  Google Scholar 

  24. Frizelle SP, Rubins JB, Zhou JX (2000) Gene therapy of established mesothelioma xenograft with recombinant p16INK4a adenovirus. Cancer Gene Ther 7:1421–1425

    Article  CAS  PubMed  Google Scholar 

  25. Girling DJ, Muers MF, Qian W, Lobban D (2002) Multicentre randomised controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society Medical Research Council. Semin Oncol 29:97–101

    Article  PubMed  Google Scholar 

  26. Grondin C, Sugarbaker DJ (1999) Malignant mesothelioma of the pleural space. Oncology 13:919–26

    CAS  PubMed  Google Scholar 

  27. Hillerdal G (1983) Malignant mesothelioma. Review of 4710 published cases. Br J Dis Chest 77:321–343

    CAS  PubMed  Google Scholar 

  28. Howel D, Arblaster L, Swinburne L, Schweiger M, Renvoize E, Hatton P (1997) Routes of asbestos exposure and the development of mesothelioma in an English region. Occup Environ Med 54:403–409

    CAS  PubMed  Google Scholar 

  29. Jaklitsch MT Grondin SC, Sugarbaker DJ (2001) Treatment of malignant mesothelioma. World J Surg 25:210–217

    Article  CAS  PubMed  Google Scholar 

  30. Kjaergaard J, Andersson M (2000) Incidence rates of malignant mesothelioma in Denmark predicted future number of cases among men. Scand J Work Environ Health 26:112–117

    CAS  PubMed  Google Scholar 

  31. Kramer G, Gans S, Rijnders A, Leer JW (2000) Long term survival of a patient with malignant pleural mesothelioma as a late complication of radiotherapy for Hodgkin’s disease with90yttrium-silicate. Lung Cancer 27:205–208

    Article  CAS  PubMed  Google Scholar 

  32. Kucharczuk JC, Kaiser LR (1997) Use of a replication restricted herpes virus to treat experimental human malignant mesothelioma. Cancer Res 57:466–471

    CAS  PubMed  Google Scholar 

  33. Lanphear BP, Buncher RC (1992) Latent period for malignant mesothelioma of occupational origin. J Occup Med 34:718

    CAS  PubMed  Google Scholar 

  34. Livitra EJ, Vyas V, Nelson K, Musanti R, Beers St, Thomas C, Poplin E, Smith S, Lin Y, Schaaf LJ, Aisner J, Gounder M, Rajendra R, Saleem A, Toppmeyer D, Rubin EH (2003) Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. Clin Cancer Res 9:1673–1679

    PubMed  Google Scholar 

  35. McDonald AD, McDonald JC (1980) Malignant mesothelioma in North America. Cancer 46:1650–1656

    CAS  PubMed  Google Scholar 

  36. Middleton GW, Smith IE, O’Brian MER (1998) Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 9:269–273

    Article  CAS  PubMed  Google Scholar 

  37. Müller KM (1997) Mesotheliome: Pathologie/Pathogenese/Mesotheliomregister. Pneumologie 51:335–344

    PubMed  Google Scholar 

  38. Neumann V, Müller KM, Fischer M (1999) Peritoneale Mesotheliome—Häufigkeiten und Ätiologie. Pathologe 20:169–176

    CAS  PubMed  Google Scholar 

  39. Neumann V, Günther S, Müller KM, Fischer M (2001) Malignant mesothelioma—German mesothelioma register 1987 to 1999. Int Arch Occup Environ Health 74:383–395

    Article  CAS  PubMed  Google Scholar 

  40. Ng DC, Hain SF, O’Doherty MJ, Dussek J (2000) Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 41:1443–1444

    CAS  Google Scholar 

  41. Otto H (1980) Das berufsbedingte Mesotheliom in der BRD. Pathologe 2:8–18

    CAS  PubMed  Google Scholar 

  42. Peto J, Decarli A, LaVecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79:666–672

    Article  CAS  PubMed  Google Scholar 

  43. Rieck G, Neumann V, Müller KM, Fischer M (2002) Lange Überlebenszeiten bei Patienten mit malignen Mesotheliomen—Gibt es einen Bezug zur histologischen Subtypisierung? Atemw Lungenkrkh 28:371–372

    Google Scholar 

  44. Robinson B (2002) Biology and gene therapy of malignant mesothelioma. Second Heidelberg thoracic oncology symposium: diagnosis and treatment of pleural mesothelioma in Heidelberg, limited handout, German Thoraxklinik, Heidelberg, Germany

    Google Scholar 

  45. Roggli VL, Oury TD, Moffatt EJ (1997) Malignant mesothelioma in women. In: Fechner RE, Rosen PP (eds) Anatomic pathology, vol 2. ASCP Press, pp 147–163

  46. Ruffie P, Feld R, Minkin S (1989) Diffuse malignant mesothelioma of the pleura in Ontario and Quebec, a retroprospective study of 332 patients. J Clin Oncol 8:1157–1168

    Google Scholar 

  47. Rusch VW, Venkatraman E (1999) Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68:1799–1802

    Article  CAS  PubMed  Google Scholar 

  48. Ryan CW, Herndorn J, Vogelzang NJ (1998) A review of chemotherapy trials for malignant mesothelioma. Chest 113:66S–73S

    CAS  PubMed  Google Scholar 

  49. Smythe WR (2002) Current therapy for malignant mesothelioma Curr Oncol Rep 4:305–313

    Google Scholar 

  50. Steele JPC, Shamasch J, Evans MT (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912–3917

    CAS  PubMed  Google Scholar 

  51. Sterman DH, Treat J, Kaiser LR (1998) Adenovirus mediated herpes simplex virus thymidine kinase ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9:1083–1092

    Google Scholar 

  52. Strizzi L, Muaro R, Vianale G, Natoli C, Talone L, Catalano A, Mutti L, Tassi G, Procopio A (2002) Expression of glycoprotein 90 k in human malignant mesothelioma: correlation with patient survival. J Pathol 197:218–223

    Article  CAS  PubMed  Google Scholar 

  53. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp, Swanson MM, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54–65

    CAS  PubMed  Google Scholar 

  54. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzmeier U, Boyer M, Emri S, Manegold C, Niykiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 15:2636–2644

    Article  Google Scholar 

  55. Wächli I, Rajower I, Christens B, Mirza S, Rüttner JR (1988) Ferruginous Bodies im Lungenstaub als Indikatoren für Asbestschäden. Pathologe 8:346–350

    Google Scholar 

  56. Wagner JC, Sleggs CA, Marchand P (1960) Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Brit J Ind Med 17:260–271

    CAS  Google Scholar 

  57. Warren WH (2000) Malignancies involving the pericardium. Semin Thorac Cardiovasc Surg 12:119–129

    CAS  PubMed  Google Scholar 

  58. Woitowitz HJ, Grossgarten K (1991) Pleuramesotheliom: Ätiologie und praktische Konsequenzen. Pneumologie 45:153–158

    CAS  PubMed  Google Scholar 

  59. Yates DH, Corrin B, Stidolph PN, Browne K (1997) Malignant mesothelioma in South East England: clinicopathological experience of 272 cases. Thorax 52:507–512

    CAS  PubMed  Google Scholar 

  60. Zellos LS, Sugarbaker DJ (2002) Diffuse malignant mesothelioma of the pleural space and its management. Oncology 16:907–913

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neumann, V., Rütten, A., Scharmach, M. et al. Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register. Int Arch Occup Environ Health 77, 191–199 (2004). https://doi.org/10.1007/s00420-003-0498-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00420-003-0498-6

Keywords

Navigation